Karen Van Baelen, Josephine Van Cauwenberge, Marion Maetens, Gabriela Beck, Ann Camden, Megan-Claire Chase, Valerie Fraser, Siobhan Freeney, Laurie Hutcheson, Julia K Levine, Tone Lien, Rian Terveer, Claire Turner, Elzbieta Senkus, Rachel C Jankowitz, Vincent Vandecaveye, Giuseppe Floris, Patrick Neven, Hans Wildiers, Elinor Sawyer, Anne Vincent-Salomon, Patrick W B Derksen, Christine Desmedt
Invasive lobular breast cancer (ILC) differs from invasive breast cancer of no special type in many ways. Evidence on treatment efficacy for ILC is, however, lacking. We studied the degree of documentation and representation of ILC in phase III/IV clinical trials for novel breast cancer treatments. Trials were identified on Pubmed and clinicaltrials.gov. Inclusion/exclusion criteria were reviewed for requirements on histological subtype and tumor measurability. Documentation of ILC was assessed and ILC inclusion rate, central pathology and subgroup analyses were evaluated...
March 20, 2024: NPJ Breast Cancer